NutriBand Inc.

NTRB

Nasdaq; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001676047

D

fourth fifth of 305 graded peers in healthcare

rank 231 of 305; percentile 75.7; sampling error 2.8 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	C percentile 52.8
Solvency	C percentile 50.9
Growth and financing	D percentile 69.2
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.5M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: dilution, distress
Inputs computable	7 of 13
Graded from	filings received through May 18, 2026 188 days before the rescan; latest periodic filing 10-Q received Sep 4, 2026
Last close	$5.14 2026-11-19; market equity $62.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 29, 2026

"we" or "us"), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA? abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs. services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 52.8						
Gross profitability	7.5%	32.8%		80.3	346	2026-01-31
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(41.2%)	(6.7%)	9.0	756	2026-01-31
Gross margin stability, five years	4.6 pts	2.8 pts	69.1	237	2026-01-31
Solvency, sleeve percentile 50.9					
Altman Z double-prime	(15.84)	0.31	71.7	705	2026-01-31
Net debt to EBITDA	not computable	1.82x			
required facts have no common fiscal period end					
Interest coverage	not computable	(3.61x)			
interest expense must exceed $100,000					
Current ratio	6.36x	2.68x	30.1	781	2026-01-31
Growth and financing, sleeve percentile 69.2					
Revenue growth, three-year compound	(0.7%)	9.6%	72.7	400	2026-01-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
one or more required annual facts are missing					
Asset growth, three years	(7.2%)	3.2%	65.7	663	2026-01-31
Net share issuance, one year	not computable	1.6%			
prior share count is 16 days earlier					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 25,543 USD; Altman Z is not used

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
226	Elanco Animal Health Inc. (ELAN)	74.0	D	
227	Tilray Brands, Inc. (TLRY)	74.3	D	fortress balance sheet
228	Cryoport, Inc. (CYRX)	74.7	D	late filer
229	Retractable Technologies Inc. (RVP)	75.0	D	short runway, fortress balance sheet
230	Precision Optics Corporation, Inc. (POCI)	75.3	D	dilution, fortress balance sheet
231	NutriBand Inc. (NTRB)	75.7	D	fortress balance sheet
232	Teleflex Inc. (TFX)	76.0	D	
233	Whitehawk Therapeutics, Inc. (WHWK)	76.3	D	
234	Vivos Therapeutics, Inc. (VVOS)	76.6	D	dilution, short runway, late filer
235	Standard Biotools Inc. (LAB)	77.0	D	late filer, fortress balance sheet
236	Baxter International Inc. (BAX)	77.3	D/E	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	11.7%	(1.7%)	56
Distance from 52-week high	(45.3%)	(33.0%)	38
EBIT to enterprise value	(14.8%)	0.5%	27
Free cash flow yield	(8.6%)	0.6%	30
Book value to price	0.09	0.29	22
Sales to price	0.03	0.38	6
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	(0.06)	(0.19)	56
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-01-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$3.4M
Operating cash flow, four quarters	-$3.6M
Months of runway	11.3
Days since last periodic filing	79 (10-Q received Sep 4, 2026)
Median daily dollar volume, 63 sessions	$182,289

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$566,308	2026-01-31	2026-04-29	10-K	26-049399
2	assets	us-gaap:Assets	$7.5M	2026-01-31	2026-04-29	10-K	26-049399
3	net income	us-gaap:NetIncomeLoss	-$8.2M	2026-01-31	2026-04-29	10-K	26-049399
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$5.1M	2026-01-31	2026-04-29	10-K	26-049399
5	assets	us-gaap:Assets	$7.5M	2025-01-31	2026-04-29	10-K	26-049399
6	revenue	us-gaap:Revenues	$2.0M	2026-01-31	2026-04-29	10-K	26-049399
7	gross profit	us-gaap:GrossProfit	$743,317	2025-01-31	2026-04-29	10-K	26-049399
8	revenue	us-gaap:Revenues	$2.1M	2025-01-31	2026-04-29	10-K	26-049399
9	revenue	us-gaap:Revenues	$2.1M	2024-01-31	2025-04-28	10-K	25-036201
10	cost of revenue	us-gaap:CostOfRevenue	$1.2M	2024-01-31	2025-04-28	10-K	25-036201
11	gross profit	us-gaap:GrossProfit	$750,404	2023-01-31	2023-04-26	10-K	23-032682
12	revenue	us-gaap:Revenues	$2.1M	2023-01-31	2024-05-01	10-K	24-037996
13	gross profit	us-gaap:GrossProfit	$554,310	2022-01-31	2023-04-26	10-K	23-032682
14	revenue	us-gaap:Revenues	$1.4M	2022-01-31	2023-04-26	10-K	23-032682
15	current assets	us-gaap:AssetsCurrent	$5.0M	2026-01-31	2026-04-29	10-K	26-049399
16	current liabilities	us-gaap:LiabilitiesCurrent	$784,281	2026-01-31	2026-04-29	10-K	26-049399
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$46.7M	2026-01-31	2026-04-29	10-K	26-049399

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

18	operating income	us-gaap:OperatingIncomeLoss	-$8.3M	2026-01-31	2026-04-29	10-K	26-049399
19	book equity	us-gaap:StockholdersEquity	$6.7M	2026-01-31	2026-04-29	10-K	26-049399
20	liabilities	us-gaap:Liabilities	$868,447	2026-01-31	2026-04-29	10-K	26-049399
21	operating income	us-gaap:OperatingIncomeLoss	-$4.9M	2024-01-31	2025-04-28	10-K	25-036201
22	interest expense	us-gaap:InterestExpense	$75,815	2024-01-31	2024-05-01	10-K	24-037996
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5,324	2026-01-31	2026-04-29	10-K	26-049399
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$4.6M	2025-01-31	2026-04-29	10-K	26-049399
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$92,043	2025-01-31	2026-04-29	10-K	26-049399
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.5M	2024-01-31	2025-04-28	10-K	25-036201
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$51,761	2024-01-31	2025-04-28	10-K	25-036201
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$3.0M	2023-01-31	2024-05-01	10-K	24-037996
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$79,304	2023-01-31	2024-05-01	10-K	24-037996
30	assets	us-gaap:Assets	$7.5M	2024-01-31	2025-04-28	10-K	25-036201
31	assets	us-gaap:Assets	$9.5M	2023-01-31	2024-05-01	10-K	24-037996
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	0	2026-05-15	2026-05-18	10-K/A	26-058507
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,155,983	2026-04-29	2026-04-29	10-K	26-049399

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.